Drug Profile
Research programme: hepatitis C virus NS5A polymerase inhibitors - Genelabs
Latest Information Update: 19 Apr 2011
Price :
$50
*
At a glance
- Originator Genelabs Technologies
- Class Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 07 Jan 2009 Genelabs Technologies has been acquired by GlaxoSmithKline
- 04 Mar 2008 Preclinical development is ongoing
- 07 May 2007 Development of this programme is ongoing